Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Operating Expenses (2018 - 2025)

BioNexus Gene Lab's Operating Expenses history spans 8 years, with the latest figure at $1.1 million for Q4 2025.

  • Quarterly results put Operating Expenses at $1.1 million for Q4 2025, down 24.86% from a year ago — trailing twelve months through Dec 2025 was $2.4 million (down 34.8% YoY), and the annual figure for FY2025 was $4.5 million, down 9.18%.
  • Operating Expenses for Q4 2025 was $1.1 million at BioNexus Gene Lab, down from $1.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $6.2 million in Q3 2023 to a low of -$4.0 million in Q4 2023.
  • The 5-year median for Operating Expenses is $873601.0 (2022), against an average of $844452.8.
  • The sharpest move saw Operating Expenses surged 722.11% in 2021, then plummeted 506.52% in 2023.
  • Year by year, Operating Expenses stood at $616816.0 in 2021, then surged by 58.19% to $975716.0 in 2022, then plummeted by 506.52% to -$4.0 million in 2023, then surged by 135.31% to $1.4 million in 2024, then dropped by 24.86% to $1.1 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $1.1 million, $1.2 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.